Protalix BioTherapeutics, Inc. Share Price
AMEX: PLX | Micro CapProtalix BioTherapeutics, Inc. Stock Performance
Open $2.55 | Prev. Close $2.61 | Circuit Range N/A |
Day Range $2.53 - $2.61 | Year Range $1.52 - $3.19 | Volume 27,286 |
Average Traded $2.57 |
Protalix BioTherapeutics, Inc. Share Price Today
As of 29 August 2026, Protalix BioTherapeutics, Inc.'s share price is $2.53. The stock opened at $2.55, compared to its previous close of $2.61. During today's trading session, Protalix BioTherapeutics, Inc.'s share price traded between $2.53 and $2.61, with an average price of $2.57. Over the past 52 weeks, the stock has recorded a high of $3.19 and a low of $1.52. In terms of performance, Protalix BioTherapeutics, Inc.'s share price has declined by 12.15% over the last six months and is up 63.23% on a year-on-year basis.
Protalix BioTherapeutics, Inc. Share Price Chart
Protalix BioTherapeutics, Inc. Stock Fundamentals & Key Indicators
Market Cap $198.72M | PE Ratio (TTM) -31.62 | Dividend Yield N/A |
EPS (TTM) $-0.08 | Revenue (TTM) $52.74M | Return On Equity (TTM) -13.69% |
Profit Margin -12.52% | Debt to Equity 0.55 | Quarterly Earnings Growth YoY -27.22% |
Protalix BioTherapeutics, Inc. Quarterly Profit & Loss
All figures in USD
Protalix BioTherapeutics, Inc. Annual Profit & Loss
All figures in USD
About Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. It operates in the United States, Australia, Canada, Israel, Brazil, Russia, and Turkey. The company is headquartered in Hackensack. New Jersey.
Protalix BioTherapeutics, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $2.45 | $2.61 | +9.66% |
Jul 2026 | $2.33 | $2.38 | +2.81% |
Jun 2026 | $2.10 | $2.31 | +9.98% |
May 2026 | $2.14 | $2.10 | -1.64% |
Apr 2026 | $2.21 | $2.14 | -2.28% |
Mar 2026 | $2.80 | $2.19 | -23.96% |
Feb 2026 | $2.35 | $2.88 | +24.14% |
Jan 2026 | $1.83 | $2.32 | +29.25% |
Dec 2025 | $1.77 | $1.79 | +0.28% |
Nov 2025 | $2.38 | $1.79 | -24.63% |
Oct 2025 | $2.23 | $2.38 | +6.50% |
Sep 2025 | $1.63 | $2.23 | +43.87% |
PLX Share Price FAQs
What is Protalix BioTherapeutics, Inc. share price today?
What is the 52 week high and 52 week low of Protalix BioTherapeutics, Inc. stock?
What is PLX's market capitalisation today?
What is PLX's net income for the last quarter?
What is the 5 year returns of PLX?
What is the high & low stock price of PLX today?
Can I buy PLX shares in India?